UCB/€UCB

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About UCB

UCB SA, founded in 1928, is a global biopharmaceutical company headquartered in Brussels, Belgium. The company specializes in the research, development, and commercialization of innovative therapies primarily for the treatment of neurological and immunological disorders. Operating in the healthcare sector, UCB is dedicated to advancing science and addressing unmet medical needs for patients worldwide.

Ticker

€UCB

Primary listing

BSE

Industry

Pharmaceuticals
Headquarters

Employees

9,215

ISIN

BE0003739530

UCB Metrics

BasicAdvanced
€33B
31.09
€5.61
0.34
€0.97
0.56%

What the Analysts think about UCB

Analyst ratings (Buy, Hold, Sell) for UCB stock.

Bulls say / Bears say

Citi has reiterated a price target of €161 on UCB shares, citing a 'compelling growth outlook' driven by the company's robust product pipeline and consistent dividend history. (Investing.com)
Jefferies has upgraded UCB to 'buy' from 'hold,' increasing peak sales forecasts for the biopharma company's skin disease treatment, Bimzelx, indicating strong market potential. (TradingView News)
UCB's net income is expected to grow this year, suggesting that the market is optimistic about its future earnings potential. (Investing.com)
UCB's return on equity (ROE) is significantly lower than the industry average of 13%, and its net income has shrunk at a rate of 12% over the last five years, indicating potential operational inefficiencies. (Webull)
The company's high three-year median payout ratio of 60% suggests that most profits are being distributed to shareholders, leaving limited funds for reinvestment and potentially hindering future growth. (Webull)
UCB's P/E ratio of 32.1x is substantially higher than the Belgian market average of below 13x, which may indicate overvaluation and could deter potential investors. (Webull)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.

UCB Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

UCB Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €UCB

Sign up or log in to buy
Capital at risk
Extended hours trading

Upcoming events

No upcoming events
FAQs